Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZYME 
Zymeworks Inc. Common Stock (ZYME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/30/2025: ZYME (4-star) is a REGULAR-BUY. BUY since 33 days. Profits (-1.22%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $21.56
1 Year Target Price $21.56
| 7 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 73.52% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 21.56 |
Price to earnings Ratio - | 1Y Target Price 21.56 | ||
Volume (30-day avg) 10 | Beta 1.19 | 52 Weeks Range 9.03 - 17.70 | Updated Date 07/30/2025 |
52 Weeks Range 9.03 - 17.70 | Updated Date 07/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When After Market | Estimate -0.46 | Actual - |
Profitability
Profit Margin -121.73% | Operating Margin (TTM) -94.48% |
Management Effectiveness
Return on Assets (TTM) -13.89% | Return on Equity (TTM) -29.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 764322262 | Price to Sales(TTM) 10.83 |
Enterprise Value 764322262 | Price to Sales(TTM) 10.83 | ||
Enterprise Value to Revenue 8.18 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 74844496 | Shares Floating 35658437 |
Shares Outstanding 74844496 | Shares Floating 35658437 | ||
Percent Insiders 0.15 | Percent Institutions 102.74 |
Upturn AI SWOT
Zymeworks Inc. Common Stock
Company Overview
History and Background
Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Founded in 2003, it has evolved from a platform technology company to a developer of clinical-stage drug candidates.
Core Business Areas
- Therapeutic Development: Focuses on discovering and developing novel biotherapeutics, primarily in oncology. This includes bispecific antibodies, antibody-drug conjugates (ADCs), and other protein-based therapies.
- Technology Platform: Zymeworks' core technology platforms, Azymetricu2122 and EFECTu2122, enable the development of innovative multifunctional biotherapeutics.
Leadership and Structure
Zymeworks' leadership team consists of experienced executives in the biotechnology industry. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Zanidatamab: A HER2-targeted bispecific antibody. Currently in clinical trials for various HER2-expressing cancers. Competitors include companies developing similar HER2-targeted therapies, such as Roche (with Herceptin and Perjeta) and Daiichi Sankyo (with Enhertu). Market share data is not yet available as the product is not yet commercialized.
- ZW171: A bispecific antibody targeting EGFR and cMET currently in clinical trials. Competitors include companies developing EGFR and cMET inhibitors. Market share data is not yet available as the product is not yet commercialized.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and a long development timeline. There's a growing focus on targeted therapies and personalized medicine.
Positioning
Zymeworks is positioned as an innovator in the field of multifunctional biotherapeutics, leveraging its proprietary technology platforms to develop differentiated therapies. Its competitive advantage lies in its bispecific antibody and ADC platforms.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is substantial, estimated to be hundreds of billions of dollars. Zymeworks is positioned to capture a portion of this market with its pipeline of innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (Azymetricu2122 and EFECTu2122)
- Experienced management team
- Strong pipeline of clinical-stage drug candidates
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Limited revenue stream (primarily from partnerships)
- High R&D expenses
- Dependence on clinical trial success
- Relatively small company size compared to major competitors
Opportunities
- Potential for regulatory approval of its lead drug candidates
- Expansion of its pipeline through internal R&D and partnerships
- Application of its technology platforms to other therapeutic areas
- Increasing demand for targeted therapies
Threats
- Clinical trial failures
- Competition from other biopharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- RHHBY
- DSNKY
- MRTX
Competitive Landscape
Zymeworks competes with both large pharmaceutical companies and smaller biotechnology companies in the oncology space. Its competitive advantage lies in its innovative technology platforms and pipeline of multifunctional biotherapeutics. Roche and Daiichi Sankyo have established products but Zymeworks is trying to disrupt and create it's own market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by strategic partnerships and advancements in its clinical pipeline.
Future Projections: Future growth is dependent on the success of its clinical trials and potential commercialization of its drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its pipeline through internal R&D and partnerships, and strengthening its financial position.
Summary
Zymeworks is a clinical-stage biopharmaceutical company with promising technology but faces risks associated with clinical trials. The company's success hinges on the regulatory approval and commercialization of its lead drug candidates. Strategic partnerships and continued innovation will be critical for its long-term growth. The lack of established products and consistent revenue is a concern and needs to be addressed. Clinical trial failures can negatively affect performance, so Zymeworks must continue to show positive results.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News Articles
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zymeworks Inc. Common Stock
Exchange NASDAQ | Headquaters Middletown, DE, United States | ||
IPO Launch date 2017-04-28 | Chairman of the Board, CEO & President Mr. Kenneth H. Galbraith C.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 299 | Website https://www.zymeworks.com |
Full time employees 299 | Website https://www.zymeworks.com | ||
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.